{"id":"dc-ctl","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Cytokine release syndrome"},{"rate":"20-30%","effect":"Neutropenia"},{"rate":"10-20%","effect":"Anemia"},{"rate":"10-20%","effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL2447913","moleculeType":"Small molecule","molecularWeight":"456.26"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"DC-CTL works by extracting T cells from a patient's blood, modifying them to recognize specific cancer antigens, and then reinfusing them into the patient's body where they can target and destroy cancer cells. This approach allows for a personalized and targeted treatment approach.","oneSentence":"DC-CTL is a type of immunotherapy that uses genetically modified T cells to target and kill cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:31:24.019Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory B-cell acute lymphoblastic leukemia"},{"name":"Relapsed or refractory diffuse large B-cell lymphoma"}]},"trialDetails":[{"nctId":"NCT05773859","phase":"PHASE1, PHASE2","title":"NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2023-03-17","conditions":"Epithelial Ovarian Cancer, Ovarian Carcinoma","enrollment":10},{"nctId":"NCT06739226","phase":"PHASE1, PHASE2","title":"Combination Immunotherapy Targeting Melanoma","status":"RECRUITING","sponsor":"Shenzhen Geno-Immune Medical Institute","startDate":"2025-08-31","conditions":"Melanoma","enrollment":30},{"nctId":"NCT05457959","phase":"PHASE1","title":"Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant","status":"WITHDRAWN","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-12-01","conditions":"Diffuse Hemispheric Glioma, H3 G34-Mutant","enrollment":""},{"nctId":"NCT06524024","phase":"NA","title":"Clinical Study of Tumor Polypeptide DC-CTL in the Treatment of Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Zhengzhou Revo-Gene Technology Co., LTD","startDate":"2025-03-11","conditions":"Solid Tumor","enrollment":20},{"nctId":"NCT04967196","phase":"PHASE1","title":"Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2021-09-16","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma","enrollment":6},{"nctId":"NCT05277753","phase":"PHASE1","title":"NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL","status":"UNKNOWN","sponsor":"Shenzhen Geno-Immune Medical Institute","startDate":"2022-03-15","conditions":"T-Cell Acute Lymphoblastic Leukemia","enrollment":10},{"nctId":"NCT05262673","phase":"PHASE1","title":"NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL","status":"UNKNOWN","sponsor":"Shenzhen Geno-Immune Medical Institute","startDate":"2022-03-01","conditions":"B-Cell Acute Lymphoblastic Leukemia","enrollment":10},{"nctId":"NCT02851784","phase":"PHASE2, PHASE3","title":"Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2009-12","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT04672473","phase":"PHASE1, PHASE2","title":"Treatment of Malignant Tumors With Antigen Peptide-specific DC-CTL Cells and Decitabine","status":"UNKNOWN","sponsor":"Shenzhen University General Hospital","startDate":"2020-10-30","conditions":"Malignant Tumor","enrollment":60},{"nctId":"NCT04567069","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study for MG-7-DC Vaccine in Gastric Cancer Treatment","status":"UNKNOWN","sponsor":"The Second Hospital of Shandong University","startDate":"2020-09","conditions":"Gastric Cancer","enrollment":45},{"nctId":"NCT04276896","phase":"PHASE1, PHASE2","title":"Immunity and Safety of Covid-19 Synthetic Minigene Vaccine","status":"UNKNOWN","sponsor":"Shenzhen Geno-Immune Medical Institute","startDate":"2020-03-24","conditions":"Pathogen Infection Covid-19 Infection","enrollment":100},{"nctId":"NCT02026362","phase":"PHASE1, PHASE2","title":"Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).","status":"SUSPENDED","sponsor":"HRYZ Biotech Co.","startDate":"2013-07","conditions":"Hepatocellular Carcinoma","enrollment":100},{"nctId":"NCT02602249","phase":"PHASE1","title":"Clinical Safety and Preliminary Efficacy of MUC1-DC-CTL Treatment in Stage IV Gastric Cancer.","status":"UNKNOWN","sponsor":"Beijing Doing Biomedical Co., Ltd.","startDate":"2017-10","conditions":"Gastric Cancer","enrollment":24},{"nctId":"NCT03205930","phase":"PHASE1, PHASE2","title":"Neo-MASCT Immunotherapy for Advanced NSCLC.","status":"UNKNOWN","sponsor":"The First People's Hospital of Lianyungang","startDate":"2017-08","conditions":"NSCLC Stage IV","enrollment":20},{"nctId":"NCT03047525","phase":"PHASE1, PHASE2","title":"Study of DC-CTL Combined With CIK for Advanced Solid Tumor","status":"UNKNOWN","sponsor":"Xiaoyi Huang","startDate":"2017-02-20","conditions":"Colorectal Cancer, Renal Cell Carcinoma, Nasopharyngeal Carcinoma","enrollment":200},{"nctId":"NCT02844881","phase":"PHASE1, PHASE2","title":"Study of Apatinib and MASCT in Patients With Advanced Solid Tumors","status":"UNKNOWN","sponsor":"The First People's Hospital of Lianyungang","startDate":"2016-07","conditions":"Advanced Solid Tumors, Excluding T Cell Lymphoma","enrollment":60},{"nctId":"NCT02858232","phase":"PHASE1, PHASE2","title":"MASCT-I Treatment for Advanced Solid Tumor","status":"UNKNOWN","sponsor":"The First People's Hospital of Lianyungang","startDate":"2016-08","conditions":"Solid Tumors","enrollment":46},{"nctId":"NCT02787915","phase":"PHASE1, PHASE2","title":"DC1s-CTL Cellular Therapy for Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"Xuzhou Medical University","startDate":"2016-09","conditions":"Renal Cell Carcinoma","enrollment":50},{"nctId":"NCT02766348","phase":"PHASE2","title":"Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients","status":"UNKNOWN","sponsor":"Shenzhen Hornetcorn Bio-technology Company, LTD","startDate":"2016-05","conditions":"NSCLC","enrollment":60},{"nctId":"NCT01637805","phase":"PHASE1","title":"Clinical Safety and Preliminary Efficacy of AAV-DC-CTL Treatment in Stage IV Gastric Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2012-05","conditions":"Stage IV Gastric Cancer","enrollment":30},{"nctId":"NCT02496273","phase":"PHASE1","title":"Phase I Trial of CEA Specific AAV-DC-CTL Treatment in Stage IV Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First People's Hospital of Changzhou","startDate":"2016-01","conditions":"Gastric Cancer","enrollment":60},{"nctId":"NCT02632006","phase":"PHASE1, PHASE2","title":"Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Second Military Medical University","startDate":"2015-09","conditions":"Advanced Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT02632201","phase":"PHASE1, PHASE2","title":"Immunotherapy Using Pluripotent Killer-Human Epidermal Growth Factor Receptor-2 (PIK-HER2) Cells for the Treatment of Advanced Gastric Cancer With Liver Metastasis","status":"UNKNOWN","sponsor":"Second Military Medical University","startDate":"2015-09","conditions":"Liver Metastasis, Gastric Cancer","enrollment":40},{"nctId":"NCT02529579","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2015-06","conditions":"Carcinoma, Pancreatic Ductal","enrollment":187}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"DC-CTL","genericName":"DC-CTL","companyName":"Shenzhen Hornetcorn Bio-technology Company, LTD","companyId":"shenzhen-hornetcorn-bio-technology-company-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"DC-CTL is a type of immunotherapy that uses genetically modified T cells to target and kill cancer cells. Used for Relapsed or refractory B-cell acute lymphoblastic leukemia, Relapsed or refractory diffuse large B-cell lymphoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}